UNSPSC 51373474: Hydrocodone/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373474 Hydrocodone/phenylpropanolamine is a Commodity code that in practice encompasses naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and OTC products procured by state and local health and safety agencies. Recent state and local solicitations under this code reflect demand for opioid-response medications and harm-reduction equipment as well as broader pharmaceutical supply contracts. Issuing bodies include county health departments and state-level cooperative purchasing alliances. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, are active recent buyers under or near this code's scope. The work involves supply of finished pharmaceutical products and medical devices with specific National Drug Code (NDC) requirements, cGMP and DSCSA compliance, and quarterly or ongoing delivery to designated facilities or through authorized wholesaler networks.

Activity is concentrated in Florida and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; bids closed July 26, 2023. MMCAP released RFP S1070000015802 on January 20, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The MMCAP solicitation requires participation through three authorized wholesalers, cGMP certification, $5 million commercial general liability insurance, and pricing evaluation weighted 75 percent on competitiveness. Both opportunities are open to vendor response with no explicit set-aside restrictions named in the source materials.